{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:51:57Z","timestamp":1790175117338,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.thromres.2012.08.305","type":"journal-article","created":{"date-parts":[[2012,9,8]],"date-time":"2012-09-08T02:15:50Z","timestamp":1347070550000},"page":"864-870","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["PRO-PACT: Retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors"],"prefix":"10.1016","volume":"130","author":[{"given":"Guy","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guenter","family":"Auerswald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Jimenez-Yuste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Morfini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Santagostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Blanchette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2012.08.305_bb0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","article-title":"Twenty-five years' experience of prophylactic treatment in severe hemophilia A and B","volume":"232","author":"Nilsson","year":"1992","journal-title":"J Intern Med"},{"key":"10.1016\/j.thromres.2012.08.305_bb0010","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2012.08.305_bb0015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1538-7836.2009.03650.x","article-title":"Efficacy and safety of secondary prophylactic vs. on-demand sucrose formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study","volume":"8","author":"Collins","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2012.08.305_bb0020","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1046\/j.1365-2516.2003.00771.x","article-title":"Long-term FEIBA prophylaxis does not prevent progression of existing joint disease","volume":"9","author":"Hilgartner","year":"2003","journal-title":"Hemophilia"},{"key":"10.1016\/j.thromres.2012.08.305_bb0025","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1365-2516.2005.01143.x","article-title":"Prophylactic treatment with FEIBA of a hemophilia A patient with inhibitor: what are the costs, what are the benefits?","volume":"11","author":"Siegmund","year":"2005","journal-title":"Hemophilia"},{"key":"10.1016\/j.thromres.2012.08.305_bb0030","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2516.2006.01284.x","article-title":"A retrospective postlicensure survey of FEIBA efficacy and safety","volume":"12","author":"Dimichele","year":"2006","journal-title":"Hemophilia"},{"key":"10.1016\/j.thromres.2012.08.305_bb0035","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.20751","article-title":"Successful self-infusion of activated prothrombin complex concentrate for prophylaxis in a child with a factor VIII inhibitor","volume":"82","author":"Ohga","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.thromres.2012.08.305_bb0040","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2516.2007.01442.x","article-title":"Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with hemophilia A and inhibitors","volume":"13","author":"Leissinger","year":"2007","journal-title":"Hemophilia"},{"key":"10.1016\/j.thromres.2012.08.305_bb0045","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2516.2008.01915.x","article-title":"Prophylaxis in 10 patients with severe hemophilia A and inhibitor: different approaches for different clinical situations","volume":"15","author":"Jim\u00e9nez-Yuste","year":"2009","journal-title":"Hemophilia"},{"key":"10.1016\/j.thromres.2012.08.305_bb0050","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2516.2009.01980.x","article-title":"The benefits of prophylactic treatment with APCC in patients with hemophilia and high-titre inhibitors: a retrospective case series","volume":"15","author":"Valentino","year":"2009","journal-title":"Hemophilia"},{"key":"10.1016\/j.thromres.2012.08.305_bb0055","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1046\/j.1365-2516.2001.00553.x","article-title":"Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with hemophilia B during major orthopaedic procedures","volume":"7","author":"Cooper","year":"2001","journal-title":"Hemophilia"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2012.08.305_bb0060","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1097\/00001721-200004001-00009","article-title":"NovoSeven in immune tolerance therapy","volume":"11","author":"Brackmann","year":"2000","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.thromres.2012.08.305_bb0065","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1055\/s-0037-1616550","article-title":"Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint","volume":"86","author":"Saxon","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2012.08.305_bb0070","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2516.2005.01096.x","article-title":"Prophylactic recombinant factor VIIa in hemophilia patients with inhibitors","volume":"11","author":"Young","year":"2005","journal-title":"Hemophilia"},{"issue":"5","key":"10.1016\/j.thromres.2012.08.305_bb0075","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1365-2516.2007.01455.x","article-title":"Prophylactic treatment of hemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Hemophilia Centres","volume":"13","author":"Morfini","year":"2007","journal-title":"Hemophilia"},{"key":"10.1016\/j.thromres.2012.08.305_bb0080","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/MBC.0b013e328309907a","article-title":"\"Primary prophylaxis\" with rFVIIa in a patient with severe hemophilia A and inhibitor","volume":"19","author":"Jimenez-Yuste","year":"2008","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.thromres.2012.08.305_bb0085","first-page":"5","article-title":"Retrospective Evaluation of Secondary Episodic Prophylaxis with rFVIIa in Hemophilia Patients with Inhibitor","volume":"2","author":"Sedano","year":"2010","journal-title":"J Coagul Disord"},{"key":"10.1016\/j.thromres.2012.08.305_bb0090","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/j.1538-7836.2007.02663.x","article-title":"Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors","volume":"5","author":"Konkle","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2012.08.305_bb0095","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1056\/NEJMoa1104435","article-title":"Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors","volume":"365","author":"Leissinger","year":"2011","journal-title":"N Eng J Med"},{"key":"10.1016\/j.thromres.2012.08.305_bb0100","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1365-2516.2011.02704.x","article-title":"Patient\/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE)","volume":"18","author":"Young","year":"2012","journal-title":"Haemophilia"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384812006810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384812006810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:36:05Z","timestamp":1758735365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384812006810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0049384812006810"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2012.08.305","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PRO-PACT: Retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2012.08.305","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}